http://www.asm.org/modules/mod_image_show_gk4/cache/mSphere Direct herogk-is-651.pnglink
http://www.asm.org/modules/mod_image_show_gk4/cache/Podcast Hero Banner3gk-is-651.pnglink
http://www.asm.org/modules/mod_image_show_gk4/cache/Microbe Online Program Plannergk-is-651.pnglink
http://www.asm.org/modules/mod_image_show_gk4/cache/AAAS Fellows Bannergk-is-651.jpglink
http://www.asm.org/modules/mod_image_show_gk4/cache/Read New JMBE Bannergk-is-651.jpglink
0 1 2 3 4
Progress bar
17-01-2017mSphere Direct
17-01-2017Podcast banner
17-01-2017AAAS Fellows
17-01-2017Read new JMBE
Become a member today!
JOIN/RENEW
Submit to an ASM Journal
SUBMIT
Attend ASM Biothreats Meeting
REGISTER

 

campadelli-fiume gabriellaDr. Campadelli Fiume's research focuses on the molecular basis of herpes simplex virus (HSV) entry into susceptible cells, and on engineering of candidate oncolytic HSVs retargeted to tumor-specific receptors. HSV entry is a multistep process. First, gD binds to one of its receptors and triggers virion-cell fusion. Fusion is executed by the conserved glycoproteins gH/gL and gB. Major accomplishments by the labs were the discovery of nectin as HSV receptor, and the triggering activity of receptor-bound gD, including the identification of gD profusion domain. Current aims include identification of the role of gH/gL in fusion. Starting from this background we have modified gD and re-addressed this molecule to the tumor-specific receptor HER-2. She has provided the first proof of principle evidence that retargeted HSVs exert antitumor activity in vivo.

TPL_asm2013_SEARCH

91007